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Background: Non-Hodgkin’s Lymphomas (NHL) are common in African children, with endemic Burkitt’s lymphoma
(BL) being the most common subtype. While the role of Epstein-Barr Virus (EBV) in endemic BL is known, no data
are available about clinical presentations of NHL subtypes and their relationship to Human Immunodeficiency Virus
(HIV) infection and Epstein Barr Virus (EBV) load in peripheral blood of children in north-western, Tanzania.
Methods: A matched case control study of NHL subtypes was performed in children under 15 years of age and
their respective controls admitted to Bugando Medical Centre, Sengerema and Shirati district designated hospitals
in north-western, Tanzania, between September 2010 and April 2011. Peripheral blood samples were collected on
Whatman 903 filter papers and EBV DNA levels were estimated by multiplex real-time PCR. Clinical and laboratory
data were collected using a structured data collection tool and analysed using chi-square, Fisher and Wilcoxon rank
sum tests where appropriate. The association between NHL and detection of EBV in peripheral blood was assessed
using conditional logistic regression model and presented as odds ratios (OR) and 95% confidence intervals (CI).
Results: A total of 35 NHL cases and 70 controls matched for age and sex were enrolled. Of NHLs, 32 had BL with
equal distribution between jaw and abdominal tumour, 2 had large B cell lymphoma (DLBCL) and 1 had NHL-not
otherwise specified (NHL-NOS). Central nervous system (CNS) presentation occurred only in 1 BL patient; 19 NHLs
had stage I and II of disease. Only 1 NHL was found to be HIV-seropositive. Twenty-one of 35 (60%) NHL and 21 of
70 (30%) controls had detectable EBV in peripheral blood (OR = 4.77, 95% CI 1.71 – 13.33, p = 0.003). In addition,
levels of EBV in blood were significantly higher in NHL cases than in controls (p = 0.024).
Conclusions: BL is the most common childhood NHL subtype in north-western Tanzania. NHLs are not associated
with HIV infection, but are strongly associated with EBV load in peripheral blood. The findings suggest that high
levels of EBV in blood might have diagnostic and prognostic relevance in African children.
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Non-Hodgkin’s Lymphomas (NHLs) are common in
African population and several histological subtypes
with different clinical presentations and treatment options
have been described based on the WHO classification of
the mature B-cell neoplasm [1]. Worldwide, reports on the
incidence of lymphomas are variable, with 60% of all* Correspondence: mrkabyemera@hotmail.com
1Department of Pediatrics and Child Health, Bugando Medical Centre, P.O.
Box 1370, Mwanza, Tanzania
Full list of author information is available at the end of the article
© 2013 Kabyemera et al.; licensee BioMed Cen
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumchildhood lymphomas being classified as NHL, represen-
ting 8% of all childhood malignancies [2-4].
In Equatorial African countries, the most common sub-
type of NHL in children is endemic Burkitt’s lymphoma
(BL) [5-7], possibly due to the high prevalence of malaria,
Human Immunodeficiency Virus (HIV) and Epstein Barr
Virus (EBV) infections in this region [5]. The magnitude of
NHL in Tanzania is unknown because of the lack of a
national cancer registry. However, a recent clinical study in
north western Tanzania reported an incidence of endemic
BL of 4.2 per 100,000 [8].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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primarily on the subtype and the site of involvement.
Approximately 70% of children who present with NHL
have advanced disease (i.e., stage III or IV) and/or have
metastatic involvement including bone marrow and
central nervous system (CNS) [9-11].
Endemic BL is commonly seen in children aged 4–9 years
[12] and presents with a painful jaw tumour, loose or
disarranged teeth [13] and less commonly with abdominal
mass or paraspinal disease. However, few African studies
reported a predominance of abdomen over jaw mani-
festation [14,15]. Bone and bone marrow involvement is
unusual. Sporadic childhood BL is more evident in white,
male children and commonly presents with enlarged
lymph nodes and abdominal tumours [16].
Childhood lymphoblastic lymphoma is commonly
manifested by either intrathoracic and/or mediastinal
mass, with various forms of respiratory distress, bilateral
pleural effusions and hepatosplenomegaly [17] and
rarely involve both the CNS and bone marrow [18].
Large B-cell lymphoma presents with an abdominal or
mediastinal mass, enlarged lymph nodes and rarely
involve both the CNS and bone marrow [2].
In African children, the association between NHL and
HIV is uncertain. Two studies from Uganda and Rwanda
described a relationship between NHL and HIV infection
[19,20] but most studies, including those with cases
confirmed by histology, reported no association between
HIV and BL [21-23].
In paediatric patients, studies have reported an asso-
ciation between EBV and NHL in 21-25% of cases
[24,25] and even 100% in children with primary and
acquired immunodeficiency [26]. Moreover, 95% of en-
demic BL have been reported to be EBV positive compared
to 15 to 20% of the sporadic BL cases [4,7,8]. Both EBV
type 1 and EBV type 2 have been associated with BL, with a
predominance of EBV type 1 [17,27-30]. However, very lit-
tle is known about EBV load in peripheral blood of African
children with NHL. A study in samples from Malawi
reported higher EBV DNA loads in peripheral blood of
children with BL compared to their controls [31].
The aim of this study was to describe the subtypes and
clinical presentations of NHL in children in north-western
Tanzania and their relationship with HIV infection and
EBV load in peripheral blood.
Methods
Study area and population
This was a case control study, done in paediatric and onco-
logy wards of the three clinical centres in north-western
Tanzania, namely Bugando Medical Centre (BMC),
Sengerema and Shirati designated district hospitals in
Mwanza and Mara regions, between September 2010
and April 2011. BMC is the zonal consultant andteaching hospital located in Mwanza city; it has a 900
bed capacity and it serves around 14 million people
from 6 regions of the Lake Zone, namely Mwanza,
Kagera, Shinyanga, Tabora, Mara and Kigoma. About
five children with tumours are admitted monthly for
investigation and treatment. Sengerema and Shirati
DDH have approximately 300 and 200 bed capacities,
respectively, and they each serve around 30 and 15 cases
of childhood lymphomas every year.
Cases were enrolled if they were ≤15 years of age with a
diagnosis of NHL and if consent from caretakers to par-
ticipate in the study was obtained. Controls were included
if they were admitted to the general paediatric wards with
non-malignant conditions and were matched for age and
sex with NHL cases. Children with malignancies that
overlapped NHL, e.g. acute lymphoblastic leukaemia, and
children with relapse of NHL were excluded from the
study.
Sample size estimation
Sample size was calculated using OpenEpi software, version
2 [32], in which Fleiss formulae for case control studies was
applied to determine the appropriate sample size for a
power of 0.8 and significance level of 0.05. The minimum
sample size for cases was 1/3 (33) and for controls was 2/3
(66) making the minimum sample size of 99.
Study clinical procedures
All consecutive NHL cases were recruited until the
required sample size was attained, whereas simple
randomization was done to select two controls per each
case from all eligible patients. The investigator or trained
research assistant either admitted the patient or reviewed
the files of all eligible children within 2 days of admission
and using a structured data collection tool, demographic
data, clinical data and required investigation results were
recorded.
To collect samples for cytological or histological
diagnosis of NHL subtypes, fine needle aspiration of
the tumour was carried out, using a needle of 25 or 27
gauge and a 20 ml disposable plastic syringe, under
sedation with midazolam (0.1 mg/kg) and ketamine
(1 mg/kg), or tissue biopsy of the tumour was carried out
under general anaesthesia. In the case of an abdominal
mass, an ultrasound scan was used to guide the needle into
the tumour. Fine needle aspirate was smeared between two
standard microscope slides with one slide immediately
fixed with 95% alcohol and the other air dried and then
transported in a slide carrier to the histopathology labora-
tory. Alcohol fixed smears were stained by Papanicolaus
stain and air dried slides were prepared and stained with
Giemsa.
Tissue biopsies were taken in the operating theatre, fixed
immediately with 10% formalin and then transported to the
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haematoxylin and eosin. At least two pathologists examined
the slides under light microscopy and children with
confirmed NHL diagnosis were enrolled in this study.
Lumbar puncture was performed in order to obtain
cerebral spinal fluid (CSF) for cytological evaluation. A
sterile 22, 38 mm gauge lumbar puncture needle (BD
spinal needle) was inserted between the fourth and fifth
lumbar vertebrae and the stylet withdrawn to allow about
5 ml of CSF to freely flow through the needle into the
sterile tube which was then sent to the pathology labora-
tory to detect the presence or absence of cancer cells.
Presence of cancer cells in the CSF indicated involvement
of the CNS.
Bone marrow aspiration was performed, using a 13,5 cm
gauge bone marrow needle (Jamshidi bone marrow
aspiration needle), under sedation with midazolam and
ketamine; 1, 2 ml of bone marrow were aspirated into the
syringe and then smeared on 8 slides (4 fixed with alcohol
and 4 without fixation) that were air dried and sent to the
pathology laboratory for cytological analysis. Presence of
lymphoma cells indicated bone marrow involvement.
NHL staging was done using the St. Jude’s staging of
childhood NHL [33].
Blood was drawn from the median cubital vein and
collected in plain and EDTA bottles and then sent to the
haematology and biochemistry laboratories for analysis of
complete blood count and erythrocyte sedimentation rate,
serum creatinine, alanine amino transferase and aspartate
amino transferase.
The Tanzania national algorithm for HIV testing was
followed to determine the HIV status of both cases and
controls, using two antibody tests, the SD Bioline (SD
Standard Diagnostics, Inc) and the Determine (Determine
HIV 1/2 Serum/Plasma Assays); the second test was carried
out in samples reactive to the first test. Those samples that
were reactive to the first and second tests were considered
to be HIV positive. Discordant results were subjected to
a third test, Unigold (The Trinity Biotech PLC) [34].
Counselling on HIV testing was done and consent was
sought prior to testing. Among HIV positive children, CD4
cell count was measured using Facscount (BD, San Jose,
California, USA).
Blood collection and DNA elution
Approximately 50 μl of blood was spotted onto each circle
of Whatman 903 filter paper and then dried at room
temperature overnight. Dried Blood Spots (DBS) were
stored in individual ziplock bags containing a desiccant,
and sent to the laboratory of the Department of Surgery,
Oncology and Gastroenterology, Section of Oncology and
Immunology, University of Padova, Unit of Viral
Oncology-IOV IRCCS, Italy. From each 50 μl DBS, three
3 mm-diameter circles, equivalent to 5 μl of whole bloodeach for a total of 15 μl whole blood, were used to extract
DNA with the DNA Micro Kit (Qiagen, Hilden, Germany)
and resuspended in 50 μl final volume.
EBV-DNA quantification
To control the ability of the eluted DNA from DBS to be
amplified, 5 μl of DNA from each sample were amplified
for the human telomerase reverse transcriptase (hTERT)
located in the 5p15.33 (Gene Bank accession: AF128893),
employed as housekeeping gene. Amplification was carried
out as previously described [35]. A quantitative method
based on Multiplex Real-Time PCR assay was performed to
quantify EBV type 1 and EBV type 2, using a primer pair
for the EBNA2 gene [36,37] and the probes designed to
discriminate between EBV type 1 and EBV type 2 ( EBV
type 1: 5'-FAM-AAT CCT CCT ACC CTC TCT TTA
TGC CAT GTG TGT-TAMRA-3'; EBV type 2: 5'-Cy5
TGG GCT GTT AGT AGG GT-BBQ-3') [38]. A standard
reference curve was obtained by five-fold serial dilution of
two amplicons, one for EBV type 1 and the other for EBV
type 2, and amplification was carried out, as already
detailed [38]. The multiplex assay showed a dynamic range
from 5 to 2×105 copies. The results were expressed as
EBV-DNA copies/ml. In those who had both EBV 1 and 2,
viral levels were added and their total viral loads were ana-
lysed to investigate the association between NHL and EBV
viral load.
Statistical analysis
Data were screened and edit checks were done to
minimize data entry errors. Data were analysed with the
STATA 11 software (College Station, Texas, USA).
Categorical variables were summarized as percentages
and were analysed by Chi-square or Fisher’s exact tests
where appropriate. Continuous variables were summarized
as mean (standard deviation) or median (range) where
appropriate. EBV-DNA levels of cases and controls were
compared using Wilcoxon rank sum (Mann–Whitney) test.
The association between NHL and EBV was investigated
using conditional logistic regression model. Odds ratios
(OR) and 95% confidence intervals (CI) were determined
by maximum likelihood estimation. The data were consi-
dered significant if the p-value was < 0.05.
Ethical considerations
Ethical approval was obtained from the Joint Bugando
Medical Centre/Bugando University College of Health
Sciences research and publication committee and guide-
lines on ethical requirement for conducting research and
sample transportation outside the country were adhered to.
Confidentiality was assured and the study did not interfere
with the decision of the attending physician in case of
absence of the investigator.
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Patient characteristics of NHL cases and controls
35 NHL cases and 70 controls matched for age and sex
were enrolled in this study. Among the NHL patients,
21 (60%) were females and 14 (40%) were males (x2 = 0.92,
p-value = 0.337). Age at presentation ranged from 3 to
14 years with a peak age of 5 to 9 years (68.57%) and a
mean age of 7.48 years (SD +/− 2.77).
Of the 35 NHL cases, 32 patients had a diagnosis of BL,
2 had diffuse large B cell lymphoma (DLBCL) and 1 had
NHL-not otherwise specified (NHL-NOS). The controls
were diagnosed with sickle cell anaemia (10, 14.3%), severe
pneumonia (8, 11.4%), gastroenteritis (5, 7.1%), congenital
heart diseases (5, 7.1%), urinary tract infections (5, 7.1%),
rheumatic heart diseases (5, 7.1%), malnutrition (5, 7.1%),
tuberculosis (4, 5.7%), nephrotic syndrome (3, 4.3%) and
others infections or bleeding conditions (20, 28.8%).
Clinical presentations of NHL cases
The primary tumour site was recorded in all cases. Of the
32 BL cases, jaw and abdomen had an equal distribution;
16 cases (50%) in each tumour site. One BL patient had
both abdominal and jaw involvement. Lymph nodes were
enlarged in all non-BL NHL cases as the primary tumour
site and these involved submandibular, axillary, cervical and
inguinal lymph nodes. Axillary and inguinal lymph nodes
were enlarged in two BL cases. Fever was reported in 11Table 1 Clinical and demographic features of NHL patients
NH
BL











Lymph Node 0/32 (0%)
CNS involvement 1/32 (3.1%)




Early (I/II) 19/32 (59.3%)
Late (III/IV) 13/32 (40.7%)
a Bone marrow sampling was done in 11 only cases because of unavailability of faccases (31.4%) and anaemia in 28 cases (80%), of which 3
(10.7%) had severe anaemia (Hb ≤ 5 g/dl).
Bone marrow was involved in the patient with NHL-
NOS, whereas CNS presentation occurred in one BL pa-
tient who was a 7 years old boy and presented with a jaw
tumor involving the left eye and weakness of the lower
limbs. He was HIV negative but EBV positive and had can-
cer cells in the CSF. The majority of BL cases (19 of 32)
had an early presentation (stage I or II), while the DLBCL
and NHL-NOS had a late presentation (stage III and IV)
(Table 1). Analysis of fever, anaemia and lymph node en-
largement showed a significant association between fever
and late stage presentation (p = 0.035).
Association of NHL with HIV infection
Only 1 NHL case and two controls were found to be
HIV-seropositive. No significant association was found
between NHL and HIV infection.
Association of NHL with EBV infection, EBV subtypes and
viral load
Of the 105 DBS samples, 42 (40.0%) were found to be
positive for EBV-DNA by PCR; therefore 42 subjects had
detectable levels of EBV in their peripheral blood. Of this
subgroup of EBV positive subjects, 21 cases and 21 con-
trols (Table 2), 27 (64.3%) had EBV type 1, while 8 (19.0%)
had both subtypes (EBV type 1 and 2). There was noL subtypes Total
DLBCL NHL-NOS
2/35 (5.7%) 1/35 (2.9%) 35/35 (100%)
0/2 (0%) 0/1 (0%) 5/35 (14.3%)
2/2 (100%) 1/1 (100%) 24/35 (68.6%)
0/2 (0%) 0/1 (0%) 6/35 (17.1%)
0/2 (0%) 0/1 (0%) 14/35 (40%)
2/2 (100%) 1/1 (100%) 21/35 (60%)
0/2 (0%) 0/1 (0%) 16/35 (45.7%)
0/2 (0%) 0/1 (0%) 16/35 (45.7%)
2/2 (100%) 1/1 (100%) 3/35 (8.6%)
0/2 (0%) 0/1 (0%) 1/35 (2.9%)
0/11 (0%) 1/11 (9.1%) 1/11 (9.1%)
1/2 (50%) 1/1 (100%) 11/35 (31.4%)
1/2 (50%) 1/1 (100) 28/35 (80%)
0/2 (0%) 0/1 (0%) 19/35 (54.3%)
2/2 (100%) 1/1 (100%) 16/35 (45.6%)
ilities in two study sites.
Table 3 EBV status and demographic characteristics and








1-4 years 2 (40%) 3 (60%) 0.813
5-9 years 17 (70.8%) 7 (29.2%)
10-14 years 2 (33.3%) 4 (66.7%)
Sex
Male 10 (71.4%) 4 (28.6%) 0.22
Female 11 (52.4%) 10 (47.6%)
NHL subtype
BL 19 (59.4%) 13 (40.6%) 0.652
Non-BL 2 (66.7%) 1 (33.3%)
Primary anatomical
site
Jaw 7 (43.8%) 9 (56.2%) 0.247
Abdomen 12 (75%) 4 (25%)
Lymph nodes 2 (66.7%) 1 (33.3%)
Clinical stage
Early 10 (52.6%) 9 (47.4%) 0.332
Late 11 (68.6%) 5 (31.4%)
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(Fisher’s exact test = 1) or sex (fisher exact test = 0.213).
twenty one of 35 (60%) NHL patients had EBV detectable
in peripheral blood compared to 21 of 70 (30%) controls; a
significant association was found between NHL and EBV
(OR = 4.77, 95% CI = 1.71 – 13.33, p -value = 0.003)
(Table 2).
EBV levels were not normally distributed. Hence, a two
sample Wilcoxon rank sum test (Mann–Whitney test) was
used to analyse the median viral load distribution between
cases and controls. This analysis showed a significantly
higher median viral load in cases compared to controls
(p-value = 0.024) (Table 2).
Analysis of cases revealed no significant association
between EBV status and demographic characteristics or
clinical presentation (Table 3).
Discussion
In this study, the most common subtype of NHL was found
to be BL, a finding similar to previously reported studies
[7]. This frequency might be due to the causal relationship
between BL and co-infections with malaria and EBV in the
north-western regions of Tanzania, which are considered
part of the “lymphoma belt” of Africa. BL should therefore
be highly suspected in cases of childhood NHL.
The common age at presentation in this study was
similar to previous studies, with the majority of patients
ranging from 5 to 9 years [12,13]. However, conversely
to other studies [2,3] females were more affected than
males; this might have been due to the small number of
cases reported in this study. Nevertheless, there was no
statistically significant relationship between NHL and
gender.
The majority of patients in this study were in an early
stage of disease at presentation, possibly due to ongoing
sensitization programmes and an increase in the number of
hospitals that provide free cancer treatment in the Lake
zone regions in recent years, compared to the past treat-
ment modalities for NHL cases [2,9-11]. The increased






21/35 (60%) 21/70 (30%) 0.003
EBV sub-type
EBV-1 11/21 (52%) 16/21 (76%)
EBV-2 5/21 (24%) 2/21 (10%)
EBV type 1 & 2 5/21 (24%) 3/21 (14%)






0.024better healthcare provided by these hospitals today may
have sensitized more patients to present early for
treatment.
Jaw and abdomen were the most common primary
tumour sites in patients with BL. While other studies
reported more jaw BL in African children [14], we found
no predominance of jaw over abdominal presentation. One
reason for more jaw BL cases might be an easier access to
jaw tumours for diagnostic purposes compared to abdo-
minal tumours which require more expertise and diagnostic
facilities than were not available in the past.
Lymph nodes were involved in all non-BL NHL subtypes.
Only 1 patient presented with CNS disease, which is more
commonly observed in sporadic BL [11,14]. As previously
reported [14], bone marrow involvement was rare. How-
ever, a Brazilian study reported 23% of cases with primary
bone marrow disease [11]. We could not rule out a possible
underestimation since bone marrow sampling was not done
in all cases because of unavailability of facilities in two sites.
HIV is believed to act as a trigger in the causation or
progression of some cancers because of its ability to cause
immune depression. Only one case and two controls were
found to be HIV-seropositive and, in agreement with
previous observations [21-23], this study did not find any
significant association between childhood NHL and HIV
infection.
A statistically significant association was found between
NHL and EBV detection in peripheral blood, with a
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NHL had higher viral load in their peripheral blood than
EBV positive controls. The high level of EBV in blood may
be relevant in predicting tumour burden, prognosis and
possibly the outcome of chemotherapy. Moreover, the
strong association between NHL and EBV may suggest that
control subjects with high detectable levels of EBV in blood
might be at higher risk of developing lymphoma.
Additional community-based studies should be done in
order to identify the common EBV subtypes circulating in
Tanzanian children and to predict their causal relationship
with NHLs in Tanzania.
Conclusions
BL is the most common childhood NHL subtype in
north-western regions of Tanzania with rare CNS and
bone marrow involvement. NHLs are not associated
with HIV infection, but are strongly associated with EBV
load in blood. Children with NHL at presentation had
significantly higher frequency and higher levels of EBV
in the peripheral blood than age matched controls.
Overall, these findings suggest that EBV load in blood
might be a diagnostic and prognostic marker for the
onset and monitoring of NHL in African children. EBV
detection in blood is less invasive and expensive than
EBV detection in histological samples. Additional studies
in larger populations are required to validate the diagnostic
and prognostic value of EBV load in blood.
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